Non-invasive fi brosis scores are widely used to identify/exclude advanced fi brosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fi brosis tests in NAFLD.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in many developed countries and now aff ects 20-30% of the population, although many aff ected individuals go unrecognized (1) (2) (3) (4) . NAFLD has a variable prognosis, with the majority of patients having benign disease without associated liver-related morbidity or mortality ( 5 ) . However, approximately 40% of patients with NAFLD develop progressive fi brosis that can Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis result in cirrhosis, putting patients at risk of hepatocellular carcinoma, liver failure, and portal hypertension-related complications (6) (7) (8) (9) (10) . Th e development of advanced fi brosis (stage F3-F4) in patients with NAFLD is clinically important as it is associated with a more than threefold increased risk of mortality (all cause and liver related) compared with a reference population ( 11, 12 ) . It is therefore vital to identify patients with advanced fi brosis so that appropriate lifestyle interventions, treatment, or surveillance for complications can be initiated.
Numerous non-invasive tests for liver fi brosis have been investigated in patients with NAFLD, but to date, none have the accuracy to completely replace liver biopsy ( 13, 14 ) . Simple non-invasive fi brosis scores derived from routine clinical and biochemical indices, such as the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fi brosis 4 (FIB-4) score and NAFLD fi brosis score (NFS) have shown promise, particularly for excluding advanced fi brosis, and are therefore useful tools to risk stratify patients with NAFLD for further investigation (15) (16) (17) (18) (19) (20) . As a result, these non-invasive scores are now widely used "fi rst line" in primary and secondary care to assess fi brosis in patients with abnormal liver enzymes and suspected NAFLD ( 21 ) . Moreover, a recent Lancet Commission addressing liver disease has recommended that simple non-invasive scores be used to help identify patients with advanced fi brosis in the community ( 22 ) .
With the increasing use of simple non-invasive fi brosis markers to identify patients with advanced liver disease, it is important to recognize and mitigate against any limitations of these tests. Th e majority of patients included in the studies on which these non-invasive scores were developed were aged between 35 and 65 years, so there is potential for reduced effi cacy of these tests in patients outwith this age distribution. Th e aim of this study was to assess whether age aff ects the diagnostic performance of the AST/ALT ratio, FIB-4 score, and NFS for advanced fi brosis in a cohort of patients with biopsy-proven NAFLD. In particular, our aim was to assess the effi cacy of these non-invasive scores in younger (≤35 years) and older patients (≥65 years) with NAFLD and if necessary to derive specifi c cutoff s for use in those patients.
METHODS
Th is study included consecutive patients with biopsy-proven NAFLD who attended specialist fatty liver clinics at the Freeman Hospital, Newcastle upon Tyne, UK; Addenbrooke's Hospital, Cambridge, UK; Antwerp University Hospital, Edegem, Belgium; and Pitié-Salpêtrière Hospital, Paris, France. Th ese formed the initial ascertainment cohort. Liver biopsies were conducted as per routine clinical care for the investigation of abnormal liver function tests (raised ALT, AST, or gamma-glutamyl transferase) or to stage disease severity in patients with radiological evidence of fatty liver. Clinical and laboratory data were collected prospectively from the time of liver biopsy. Patients with evidence of other liver disease (autoimmune hepatitis, viral hepatitis, drug induced liver injury, hemochromatosis, cholestatic liver disease, or Wilson's disease) were excluded. In addition, subjects consuming excessive amounts of alcohol (alcohol intake >20 g/day for women; >30 g/day for men) at the time of biopsy or in the past were excluded. Patients with incomplete data to calculate all the non-invasive scores were excluded.
Relevant clinical details, including gender, age, weight, and height, were obtained at the time of biopsy. Th e body mass index was calculated by the formula: weight (kg)/height (m) 2 . Patients were identifi ed as having diabetes if they had been diagnosed with diabetes according to the 2004 American Diabetes Association criteria or if they were taking an oral hypoglycemic drug or insulin ( 23 ) .
Percutaneous liver biopsies were performed as per unit protocol at the sites and were assessed by an experienced local hepatopathologist. Patients with liver biopsies specimens <15 mm in length were excluded. Histological scoring was performed according to the non-alcoholic steatohepatitis (NASH) Clinical Research Network criteria ( 24 ) . Th e NAFLD activity score was graded from 0 to 8, including scores for steatosis (0-3), lobular infl ammation (0-3), and hepatocellular ballooning (0-2). NASH was defi ned as steatosis with hepatocyte ballooning and infl ammation ± fi brosis ( 25 ) . Fibrosis was staged from F0 to F4 ( 24 ) . Patients with stage F3 or F4 fi brosis were considered to have advanced fi brosis.
Th e AST/ALT ratio, FIB-4, and NFS were calculated from blood tests taken at the time of liver biopsy as previously described ( 16, 26, 27 ) . Details of the formulas and cutoff s for the tests under investigation are shown in Table 1 . Previously published cutoff s were used to exclude and diagnose advanced fi brosis for each score ( 15, 16, 18, 19 ) To validate new cutoff s for the NFS and FIB-4 score optimized for use in older patients (aged ≥65 years) that were derived in the initial ascertainment cohort, anonymized biochemical, histological, and anthropometric data were collected from a separate group of histologically characterized patients from the All statistical analyses were performed using the SPSS soft ware version 22.0 (SPSS, Chicago, IL). Continuous normally distributed variables were represented as mean ± s.d. Categorical and non-normal variables were summarized as median and range. Chi squared tests were used to determine the distribution of categorical variables between groups. To compare the means of normally distri buted variables between groups, the Student's t -test or analysis of variance test was performed. To determine diff erences between groups for continuous non-normally distributed variables, medians were compared using the Mann-Whitney U -test. Th e diagnostic performance of the non-invasive tests was assessed by receiver operating characteristic (ROC) curve analysis. Th e area under the ROC (AUROC) was used as an index to compare the accuracy of tests. Th e sensitivity, specifi city, positive predictive values (PPVs), negative predictive values (NPVs), positive likelihood ratios (LR +ve), and negative likelihood ratios (LR −ve) for relevant cutoff s were also displayed. In order to assess changes in sensitivity and specifi city of the tests with age, plots of sensitivity and specifi city in diff erent age groups were displayed graphically. New cutoff s for the FIB-4 and NFS were derived for ≥65-yearold patients by taking the point on the ROC where the combined value of sensitivity and specifi city was the highest. As the prevalence of advanced fi brosis can vary in diff erent populations, the PPVs and NPVs for the new cutoff s were displayed at advanced fi brosis prevalence rates of 5, 10, 20, 30, and 40%. A P value of <0.05 was considered signifi cant.
RESULTS

Characteristics of the whole cohort
A total of 634 patients with biopsy-proven NAFLD were included in the study, 369 from Newcastle, 138 from Antwerp, 99 from Paris, and 28 from Cambridge. Overall, 347 (55%) patients were male. Overall, the indication for liver biopsy was the assessment of "raised" transaminases (serum ALT or AST >40 IU/ml) in 464 (73%) patients and for the staging of disease in 170 (27%) patients with imaging evidence of steatosis and "normal" transaminase levels. Th e mean age was 51±12 years. Forty-three percent of the cohort were diabetic and the mean body mass index was 34.5 ± 6 kg/m 2 . In total, 461 (73%) patients had histological evidence of NASH and the median NAFLD activity score was 4 (1) (2) (3) (4) (5) (6) (7) (8) . Overall, the median fi brosis stage was F1 (F0-F4); 164 patients (25%) had advanced liver fi brosis (stage F3-F4).
Effect of age on clinical factors in patients with NAFLD
In order to assess the eff ect of age on clinical accuracy of simple non-invasive scores for NAFLD fi brosis, the cohort was stratifi ed by age into fi ve groups: ≤35, 36-45, 46-55, 56-64, and ≥65 years, respectively. Table 2 displays the clinical, biochemical, and histological features of patients in each of these age groups. Overall, increasing age was signifi cantly associated with female gender ( P <0.001) and the presence of Type 2 diabetes ( P <0.001) and NASH ( P =0.001), as well as increased fi brosis stage ( P <0.001), AST/ALT ratio ( P <0.001), NFS ( P <0.001), and FIB-4 score ( P <0.001). In addition, there was a signifi cant negative association between age and platelet count ( P <0.001), serum ALT ( P <0.001), and serum albumin ( P <0.001) Diagnostic accuracy for advanced fi brosis using simple non-invasive fi brosis scores in patients by age group A detailed summary of the AUROC, sensitivity, specifi city, PPVs, NPVs, LR+ve, and LR-ve for the AST/ALT ratio, the FIB-4 score, and the NFS is shown in Table 3 for patients divided into the fi ve age groups. Overall, the performance of the AST/ALT ratio, NFS, and FIB-4 score was very poor in the ≤35-year-old patients (AUROCs 0.52, 0.52, and 0.60, respectively, all P =NS), suggesting that these scores have insuffi cient accuracy to have a role in the management of patients with NAFLD in this age group.
Th e diagnostic accuracy of the AST/ALT ratio for advanced fi brosis was lower than the NFS and FIB-4 score across all age groups, with modest AUROCs ranging from 0.52 to 0.73. Th e NFS and FIB-4 score performed similarly well across all the age groups >35 years, with AUROCs for a diagnosis of advanced fi brosis ranging from 0.77 to 0.84. However, despite having similar AUROC for advanced fi brosis across age groups, the specifi city of the NFS and FIB-4 for advanced fi brosis fell with increasing age. Th is is illustrated in Figure 1a -c , which shows plots of the sensitivity and specifi city against age for the AST/ ALT ratio, NFS, and FIB-4 score. Using the established diagnostic cutoff s for advanced fi brosis, the specifi city of the NFS and FIB-4 scores were very low in patients aged ≥65 years (20% at cutoff −1.445 for NFS and 35% at cutoff 1.3 for FIB-4). Th is equates to an unacceptably high false positive rate for advanced fi brosis in patients aged >65 years. Th e observed decline in specifi city with increasing age is perhaps unsurprising as both the NFS and FIB-4 score incorporate age in the formula, but the fall in specifi city for advanced fi brosis with the AST/ALT ratio was unexpected.
Effects of age on specifi city of AST/ALT ratio for advanced fi brosis
Overall, there was a signifi cant negative association between age and serum ALT ( P <0.001), whereas there was no signifi cant relationship between age and AST. When the relationship between age and serum ALT in patients with no/mild fi brosis (stage F0-F1) or moderate-to-advanced fi brosis (stage F2-F4) were analyzed separately to correct for fi brosis, the signifi cant negative relationship between serum ALT and age persisted ( P <0.001 for both see Figure 2a ,b ), suggesting the age-related fall in ALT level was independent of fi brosis stage. Th is relationship also persisted when males and females were analyzed separately (data not 
Derivation of new cutoffs to exclude advanced fi brosis for the NFS and FIB-4 score in older patients (≥65 years)
As NAFLD is highly prevalent in older patients, it would be particularly advantageous to have an accurate non-invasive test for fi brosis in this age group. In light of the poor specifi city of the NFS and FIB-4 scores for advanced fi brosis when the currently published diagnostic cutoff s are employed in patients aged ≥65 years, our results imply that many patients with mild fi brosis will be wrongly classifi ed as having advanced fi brosis and so would undergo additional unnecessary investigations. To address this problem, optimized cutoff s were derived to improve specifi city and thus reduce the false positive rate. Adopting the revised threshold (FIB-4 >2.0) in patients aged ≥65 years, the sensitivity and specifi city attained for advanced fi brosis were 77% and 70%, respectively. Similarly, the new age-adjusted NFS threshold (NFS>0.12) yielded 80% sensitivity and 70% specifi city for advanced fi brosis. Plots showing the sensitivity and specifi city performance of these new thresholds across the age range are shown Figure 3a ,b . Application of the new cutoff for the NFS in patients aged >65 years substantially reduced the number of patients with intermediate scores, so that the majority were defi nitively classifi ed as low risk or high risk and would not necessarily need further investigation (percentage defi nitively categorized using the new cutoff 80% (61/76) vs. 45% (34/76) for the existing cutoff ). Th is was a substantial improvement over the performance of the existing cutoff with slightly more cases correctly classifi ed (80% vs. 76%, respectively) with respect to their histological stage. For the FIB-4 score, the new cutoff also defi nitively classifi ed more patients as low risk or high risk than the existing cutoff (82% (62/76) vs. 55% (42/76), respectively) while maintaining the correct classifi cation in 78% of cases. As PPVs and NPVs are a function of disease prevalence in the background population and the tests may be applied to populations where the prevalence of advanced fi brosis is lower than in our study cohort, the PPVs and NPVs for older patients (≥65 years) are displayed McPherson et al. ALT, alanine transaminase; AST, aspartate aminotransferase; AUROC, area under the receiver operating characteristic curve; CI, confi dence interval; FIB-4, fi brosis 4; LR +ve, positive likelihood ratio, LR −ve, negative likelihood ratio; NFS, non-alcoholic fatty liver disease fi brosis score; NPV, negative predictive value; PPV, positive predictive value; Sens., sensitivity; Spec., specifi city.
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across an advanced fi brosis prevalence scale in Table 4 , which compares performance of the existing thresholds and our proposed thresholds for the FIB-4 and NFS.
Independent validation of new cutoffs for the NFS and FIB-4 score in a separate patient cohort
In order to validate the new cutoff s for the NFS and FIB-4 score in older patients, a second cohort of 61 patients with biopsyproven NAFLD aged ≥65-years but otherwise selected according to the same criteria as the fi rst cohort was assessed. Th e mean age of these patients was similar to the mean for the age in the ≥65-years group in the ascertainment cohort at 69±3.4 years and 41 (67%) were female. Overall 54 (89%) patients had NASH, 38 (62%) were diabetic, and 24 (39%) had advanced fi brosis. Th e AUROC for a diagnosis of advanced fi brosis was 0.72 (95% confi dence interval 0.59-0.85) for both the NFS and FIB-4 score. Th e sensitivity and specifi city for advanced fi brosis in these patients was similar to the main cohort (NFS: sensitivity 71% and specifi city 68%; FIB-4 score: sensitivity 75% and specifi city 65%), confi rming their validity.
DISCUSSION
Th e use of simple non-invasive fi brosis scores such as the NFS and FIB-4 score to identify or exclude advanced fi brosis as part of a staged approach to diagnosis and risk stratifi cation in patients with NAFLD is now widely adopted and recommended by most guidelines ( 1,2,13,28 ). Previous studies have shown that these scores can reliably exclude advanced fi brosis in patients with NAFLD, and as a result, they provide a useful, inexpensive fi rstline assessment of liver fi brosis for use in primary or secondary care ( 16, 18, 19 ) . Although fi delity appears lower when applied in bariatric surgery cohorts ( 29 ) , several studies have now validated their use in large populations of patients with biopsy-proven NAFLD ( 17, 20, (30) (31) (32) . However, the majority of patients included in these studies were in middle age (typical mean age of 45-55 years), with very few younger (≤35 years) or older patients (≥65 years) included. With the widespread adoption of the FIB-4 and NFS, inevitably these tests are increasingly being used in patients outside the age range in which they have been validated. Anecdotally, we have seen quite a number of older patients referred to our fatty liver clinics with intermediate or high NFS and FIB-4 scores who have no evidence of advanced fi brosis when assessed by other methods, such as elastography or biopsy. Th erefore, the aim of the present study was to assess the performance of these simple noninvasive fi brosis scores in age-defi ned cohorts of patients of histologically characterized NAFLD, with a particular focus on cases at the younger (<35 years) and older (≥65 years) ends of the age spectrum.
One of the most notable fi ndings of this study was that, despite the FIB-4 and NFS having similar AUROCs in all age groups >35 years old, the specifi city for advanced fi brosis using the lower cutoff with these tests fell sharply in the older patients and became unacceptably low in those aged ≥65 years (specifi city 35% and 20%, respectively, for FIB-4 score and NFS). In essence, inclusion of age in the FIB-4 and NFS leads to a false infl ation of the score in patients aged >65 years, bringing more patients into the intermediate-risk bracket and increasing the high false positive rate. As a result, we have derived new lower These show a reduction in sensitivity and an increase in specifi city with age.
LIVER VOLUME 112 | MAY 2017 a signifi cant age-related fall in serum ALT levels, which persisted, independent of fi brosis stage and gender, and confi rms results of previous studies (33) (34) (35) . As both the NFS and FIB-4 score include a ratio of the AST and ALT in their models, this may well also contribute to the overall reduction in specifi city with increasing age. Serum ALT levels are well known to fall with increasing fi brosis stage, so one explanation for this observation may be that, with a higher prevalence of advanced fi brosis in older patients, the ALT fall in the older patients was due to increased fi brosis stage. However, re-analysis of the data stratifi ed by fi brosis stage demonstrates that this is not the explanation and so the underlying mechanism for the fall in ALT levels is not known. It is, however, consistent with the observation that many NAFLD patients have serum ALT levels within the normal range, irrespective of disease activity. It once again highlights that clinicians should not rely on a raised serum ALT to support a diagnosis of NAFLD or as a marker of disease severity, particularly in older individuals. It also raises the broader question of whether age-specifi c normal ranges for serum ALT should be defi ned. Th erefore, the likely explanation for the reduced specifi city of the AST/ALT ratio for advanced fi brosis is that, even in the absence of liver disease, there is a natural age-related fall in serum ALT level (while the AST level remains stable). Th is increases the AST/ALT ratio and, as a result, reduces the specifi city of this test for advanced fi brosis. In addition to the eff ect of age on transaminase levels, we found a negative association between age and platelet count, confi rming previous epidemiological studies ( 36 ) . Both NFS cutoff s for the FIB-4 score and NFS for use in patients aged ≥65 years, which reduced the number of patients with an indeterminate score. Use of these thresholds in patients aged ≥65 years increased the specifi city for advanced fi brosis using the NFS and FIB-4 score to 70%, eff ectively controlling the false positive rate without adversely infl ating the false negative rate of the test. Th e upper cutoff s remained the same. Th e advantage of adopting these cutoff s was confi rmed in a separate validation cohort. We believe that introduction of these new cutoff s for older patients will have a direct benefi t to the patients by reducing the need for further unnecessary and potentially invasive investigations and will also lead to cost savings by reducing inappropriate onward referral of older patients without advanced liver disease to secondary care. A proposed algorithm for the use of the NFS and FIB-4 score that takes account of patient age is shown in Figure  4a ,b . It is important to note that even with these new cutoff s the PPV for advanced fi brosis with the FIB-4 score and NFS was relatively low if used in cohorts with a low prevalence of advanced fi brosis. Th erefore, patients with a raised score should undergo a second-line investigation to confi rm advanced fi brosis. Previous studies have shown that the major value of these simple non-invasive scores is to exclude rather than diagnose advanced fi brosis ( 19 ) . Both the NFS and the FIB-4 score include age in their models and this might be one explanation for the reduction in specifi city for advanced fi brosis with increasing age. However, we also demonstrated that the specifi city of the AST/ALT ratio for advanced fi brosis fell with increasing age. Th is was due to 
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and FIB-4 score include platelet count in their models, likely also contributing to the observed reduction in specifi city with increasing age. Another key fi nding of this study was that the AST/ALT ratio, NFS, and FIB-4 scores performed very poorly in patients aged <35 years. In this age group, the AUROCs for advanced fi brosis for all three non-invasive scores did not reach statistical signifi cance, suggesting that these scores are inaccurate and therefore should not be used to diagnose or exclude advanced fi brosis. Th e prevalence of advanced fi brosis was relatively low in this group compared with older patients, with 11% of subjects having stage F3 fi brosis and none being cirrhotic. Th e low prevalence of advanced fi brosis might be one explanation for the poor performance of these tests in this age group.
In the United Kingdom, a recent Lancet Commission has set out a blueprint that aims to reduce premature mortality rates from liver disease and a key aspect of this is early recognition of patients with progressive and advanced liver disease in the community ( 22 ) . One of the recommendations of this report is that all liver function test requests in the community should have both ALT and AST measured and the AST/ALT ratio should be displayed on the laboratory report. AST/ALT ratios >1 are to be fl agged to clinicians to recommend further liver assessment. Despite having looked very promising in some previous studies, the AST/ALT ratio performed relatively poorly in the present study with an overall AUROC of 0.70 for a diagnosis of advanced fi brosis ( 15, 19 ) . Results of the present study and others suggest that it might be more benefi cial to use the FIB-4 score or NFS as an alternative to the AST/ALT ratio as these appear more accurate ( 18, 37, 38 ) . Although these are more complex to calculate, the FIB-4 score only requires the addition of the age and platelet count to the AST and ALT and a simple online calculator is available ( http://gihep.com/calculators/hepatology/fi brosis-4-score/ ).
It is salutatory to note that, as with the FIB-4 and NFS, many of the other non-invasive tests for fi brosis that are used in clinical practice have not been validated for use in older-age cohorts, particularly when NASH and advanced fi brosis are seen more commonly on biopsy in older patients ( 39 ) . Complex fi brosis panels that include markers of matrix turnover, such as the Enhanced Liver fi brosis panel and FibroTest, have shown promise for the assessment of liver fi brosis in NAFLD ( 40, 41 ) . However, these panels have been primarily developed in young and middle-aged patients with few patients aged ≥65 years studied. Th e Enhanced Liver fi brosis test may be less susceptible to an age-related bias as it does not include age in its mathematical model; however, there is published evidence that the test exhibits reduced diagnostic accuracy when age is >45 years and so clarifi cation of this point is needed ( 42 ) . Further evaluation in older patients is clearly warranted before accuracy can be assumed in older patients. Another commonly adopted method for non-invasive assessment of fi brosis is liver stiff ness measurement assessed by transient elastography. Th is technique is generally eff ective at excluding advanced fi brosis when reliable readings can be obtained and may perform better than simple non-invasive fi brosis tests ( 43 ) . However, large studies have demonstrated that an insuffi cient number of valid measurements may be achieved in some patients owing to adiposity and body habitus. Indeed, even when using the Fibroscan XL probe, which is adapted for obese patients, a valid result may not be achieved in up to 26% of subjects ( 44 ) . In large-scale retrospective studies, older age (>52 years), along with central obesity and Type 2 diabetes mellitus, were the key independent factors predictive of failure to achieve valid liver stiff ness measurement ( 45 ) . Th ere is also recent evidence from an epidemidemiological study that liver stiff ness may rise with age ( 46 ) , suggesting that this test too may have reduced utility in older patients with NAFLD.
Age-related changes in liver morphology may also contribute to the eff ect of increasing age on the performance of noninvasive fi brosis tests, including elastography. Liver blood fl ow and liver mass are known to be reduced in the ageing liver ( 47 ) . prevalence. To counter this concern, as prevalence can vary in different populations, we have displayed PPVs and NPVs at diff erent prevalence rates for the new derived cutoff s to aid clinicians using these scores in diff erent clinical settings. Finally, histological assessment of liver fi brosis is an imperfect gold standard that is subject to both the eff ect of non-uniform distribution of histological lesions throughout the liver parenchyma and ascertainment variation (50) (51) (52) . Liver biopsies were analyzed by a local pathologist at each of the centers. Although all the pathologists reading the biopsies are highly experienced hepatopathologists, there is potential for interobserver variability, which may have led to a lowering of the diagnostic accuracy of the tests. Despite these limitations, the overall diagnostic accuracy of the non-invasive scores assessed in the present study are in keeping with other studies and this is the fi rst study to specifi cally assess these scores in specifi c age groups ( 17, 18, 20, (30) (31) (32) .
In conclusion, this study shows that age has a signifi cant eff ect on the performance of simple non-invasive fi brosis scores in diagnosing advanced fi brosis. Th e AST/ALT ratio, FIB-4 score, and NFS performed poorly in patients aged <35 years, suggesting that clinicians should use alternative means of non-invasive diagnosis It is also recognized that vascular morphology is modifi ed with increasing age with even healthy liver exhibiting defenestration of sinusoidal endothelial cells, sinusoidal fi brosis, increased hepatic arteriolar wall thickness, and decreased arteriolar diameter that may impair oxygen-dependent hepatocyte function ( 48, 49 ) .
Th is study does have some limitations. First, the sample size of younger (≤35 years) and older patients (≥65 years) is relatively small despite a large overall cohort size, refl ecting that these patients are less likely to have a liver biopsy performed in routine clinical practice. Second, patients are likely to be highly selected, particularly the older patients (≥65 years), as clinicians tend to be reluctant to perform liver biopsy in older patients for fear of complications, unless they believe it is going to signifi cantly change the patient's management. In addition, the prevalence of Type 2 diabetes was high (38%) in the young (<35 years) patients, which suggests selection bias as this rate of diabetes is higher than would be expected in a young cohort of patients with NAFLD. Th ird, the prevalence of advanced fi brosis was high in this study, again probably refl ecting the selection bias, and this will have impacted on the PPVs and NPVs that have been displayed as they are heavily infl uenced by FIB-4, fi brosis 4; LR +ve, positive likelihood ratio, LR −ve, negative likelihood ratio; NFS, non-alcoholic fatty liver disease fi brosis score; NPV, negative predictive value; Prev., prevalence; PPV, positive predictive value; Sens., sensitivity; Spec., specifi city.
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of fi brosis in this age group. Th e overall diagnostic accuracy for advanced fi brosis using the NFS and FIB-4 score was acceptable in patients aged >35 years, but there was a signifi cant fall in specifi city for advanced fi brosis in older patients (≥65 years), resulting in a high false positive rate for advanced fi brosis. To rectify this, while the existing thresholds should continue to be used in patients aged 35-65 years, we propose new cutoff s that will signifi cantly improve the accuracy of the NFS and FIB-4 score in patients aged ≥65 years. . Proposed algorithm for the use of the ( a ) non-alcoholic fatty liver disease (NAFLD) fi brosis score (NFS) and ( b ) fi brosis 4 (FIB-4) score to help diagnose or exclude advanced fi brosis patients using the age specifi c cutoffs. The NFS and FIB-4 scores are not suitable for patients aged <35 years. Existing thresholds as previously published should be used for those aged 35-65 years. The new lower thresholds derived and validated in the current paper are recommended for those aged ≥65 years. Existing upper cutoffs remain the same for those aged ≥65 years. A full color version of this fi gure is available at the American Journal of Gastroenterology journal online.
